147 related articles for article (PubMed ID: 32251743)
21. The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Kim S; Tiedt R; Loo A; Horn T; Delach S; Kovats S; Haas K; Engstler BS; Cao A; Pinzon-Ortiz M; Mulford I; Acker MG; Chopra R; Brain C; di Tomaso E; Sellers WR; Caponigro G
Oncotarget; 2018 Oct; 9(81):35226-35240. PubMed ID: 30443290
[TBL] [Abstract][Full Text] [Related]
22. Corrigendum to "Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors" [Eur. J. Med. Chem. 180 (2019) 171e190].
Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
Eur J Med Chem; 2020 Jan; 186():111899. PubMed ID: 31787358
[No Abstract] [Full Text] [Related]
23. Corrigendum to "Design, synthesis and evaluation of novel thienopyrimidine-based agents bearing diaryl urea functionality as potential inhibitors of angiogenesis" [Eur. J. Med. Chem 209 (2021) 112942].
Faraji A; Oghabi Bakhshaiesh T; Hasanvand Z; Motahari R; Nazeri E; Boshagh MA; Firoozpour L; Mehrabi H; Khalaj A; Esmaeili R; Foroumadi A
Eur J Med Chem; 2021 Mar; 214():113228. PubMed ID: 33550180
[No Abstract] [Full Text] [Related]
24. Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future.
DiPippo AJ; Patel NK; Barnett CM
Pharmacotherapy; 2016 Jun; 36(6):652-67. PubMed ID: 27087139
[TBL] [Abstract][Full Text] [Related]
25. Corrigendum to <'Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d] pyrimidine analogues as novel CHK1 inhibitors' [Eur. J. Med. Chem. 151 (2018) 836-848].
Tian C; Han Z; Li Y; Wang M; Yang J; Wang X; Zhang Z; Liu J
Eur J Med Chem; 2019 Jul; 173():184. PubMed ID: 31003059
[No Abstract] [Full Text] [Related]
26. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
27. Corrigendum to "Synthesis and evaluation of 2,5-furan, 2,5-thiophene and 3,4-thiophene-based derivatives as CXCR4 inhibitors" [Eur. J. Med. Chem. 181 (2019) 111562].
Gaines T; Garcia F; Virani S; Liang Z; Yoon Y; Oum YH; Shim H; Mooring SR
Eur J Med Chem; 2023 Dec; 261():115753. PubMed ID: 37634992
[No Abstract] [Full Text] [Related]
28. Corrigendum to "A fluorine scan on the Zn
Zhang B; Liu J; Gao D; Yu X; Wang J; Lei X
Eur J Med Chem; 2020 Jul; 198():112340. PubMed ID: 32371332
[No Abstract] [Full Text] [Related]
29. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
[TBL] [Abstract][Full Text] [Related]
30. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
Spring LM; Wander SA; Andre F; Moy B; Turner NC; Bardia A
Lancet; 2020 Mar; 395(10226):817-827. PubMed ID: 32145796
[TBL] [Abstract][Full Text] [Related]
31. Corrigendum to "Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer" [Eur. J. Med. Chem. 238 (2022) 1-20/114484].
Cui H; Hu Z; Yang K; Huang J; Wu Y; Chen Q; Wei R; Wang P; Wang H; Li H; Chen Y; Lu T; Yao Y; Zhu Y
Eur J Med Chem; 2022 Oct; 240():114568. PubMed ID: 35809536
[No Abstract] [Full Text] [Related]
32. CDK4/6 inhibition in early and metastatic breast cancer: A review.
de Groot AF; Kuijpers CJ; Kroep JR
Cancer Treat Rev; 2017 Nov; 60():130-138. PubMed ID: 28961554
[TBL] [Abstract][Full Text] [Related]
33. Corrigendum to "Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer" [Eur. J. Med. Chem. 259 (2023) 115703/5].
Fang B; Lai Y; Yan H; Ma Y; Ni Z; Zhu Q; Zhang J; Ye Y; Wang M; Wang P; Wang Y; Zhang S; Hui M; Wang D; Zhao Y; Li X; Wang K; Liu Z
Eur J Med Chem; 2024 Mar; 268():116230. PubMed ID: 38368135
[No Abstract] [Full Text] [Related]
34. Corrigendum to "Optimization of physicochemical properties for 4-Anilinoquinazoline inhibitors of trypanosome proliferation" [Eur. J. Med. Chem. 141 (2017) 446-459].
Woodring JL; Bachovchin KA; Brady KG; Gallerstein MF; Erath J; Tanghe S; Leed SE; Rodriguez A; Mensa-Wilmot K; Sciotti RJ; Pollastri MP
Eur J Med Chem; 2018 May; 152():515. PubMed ID: 29754075
[No Abstract] [Full Text] [Related]
35. Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer.
Lee KA; Shepherd ST; Johnston SR
Future Oncol; 2019 Oct; 15(29):3309-3326. PubMed ID: 31464525
[TBL] [Abstract][Full Text] [Related]
36. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
37. Corrigendum to "Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview" [Eur. J. Med. Chem. 194 (2020) 112260].
Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
Eur J Med Chem; 2020 Nov; 205():112642. PubMed ID: 32750565
[No Abstract] [Full Text] [Related]
38. Corrigendum to "Pyridine and nitro-phenyl linked 1,3,4-thiadiazoles as MDR-TB inhibitors" [Eur. J. Med. Chem. 167 (2019) 1-9].
Patel H; Jadhav H; Ansari I; Pawara R; Surana S
Eur J Med Chem; 2020 Aug; 200():112413. PubMed ID: 32512481
[No Abstract] [Full Text] [Related]
39. Corrigendum to "Synthesis and preliminary antiproliferative activity of new pteridin-7(8H)-one derivatives" [Eur. J. Med. Chem. 143 (2018) 1396-1405].
Li ZH; Zhao TQ; Liu XQ; Zhao B; Wang C; Geng PF; Cao YQ; Fu DJ; Jiang LP; Yu B; Liu HM
Eur J Med Chem; 2019 Nov; 181():111387. PubMed ID: 31376565
[No Abstract] [Full Text] [Related]
40. Corrigendum to "Design, synthesis and evaluation of hybrid of tetrahydrocarbazole with 2,4-diaminopyrimidine scaffold as antibacterial agents" [Eur. J. Med. Chem. 162 (162) (2019) 203-211].
Su L; Li J; Zhou Z; Huang D; Zhang Y; Pei H; Guo W; Wu H; Wang X; Liu M; Yang CG; Chen Y
Eur J Med Chem; 2019 Apr; 168():385. PubMed ID: 30826513
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
